Keytruda's shareInsight
How much of Merck is Keytruda?
| Date | Keytruda | Total sales |
|---|---|---|
| 2024-09-30 | 7.43B | 16.66B |
| 2024-12-31 | 7.84B | 15.62B |
| 2025-03-31 | 7.21B | 15.53B |
| 2025-06-30 | 7.96B | 15.81B |
| 2025-09-30 | 8.14B | 17.28B |
| 2025-12-31 | 8.37B | 16.40B |
| 2026-03-31 | 8.03B | 16.29B |
| 2026-06-30 | 8.37B | 16.61B |
→Keytruda sold $8.4B in Q2 2026, out of $16.6B of Merck's total sales: that much of the company rests on one cancer drug, whose main US patent runs out in 2028.
Source: SEC EDGAR (8-K Exhibit 99.1) · as at 2026-06-30
Where this comes from
- Source: SEC EDGAR (8-K Exhibit 99.1) (filing)
- Which in turn reads: 8-K Exhibit 99.1, Item 2.02
- How current: As at 2026-06-30 · checked every 91 days
- What we hold: 8 observations, from 2024-09-30 to 2026-06-30
- Attribution: Read from the company's Exhibit 99.1 as filed with the SEC. Public domain; linked per figure, not reproduced.